Egaptivon pegol
Egaptivon pegol Uses, Dosage, Side Effects, Food Interaction and all others data.
ARC1779 is a therapeutic aptamer antagonist of the A1 domain of von Willebrand Factor (vWF), the ligand for receptor glycoprotein 1b on platelets. ARC1779 is being developed as a novel antithrombotic agent for use in patients with acute coronary syndromes. ARC1779 is a therapeutic oligonucleotide ("aptamer") which blocks the binding of the A1 domain of vWF to the platelet GPIb receptor, and thereby modulates platelet adhesion, activation, and aggregation under the high shear conditions of coronary arterial stenosis and plaque rupture.
| Trade Name | Egaptivon pegol |
| Generic | Egaptivon pegol |
| Egaptivon pegol Other Names | Egaptivon pegol |
| Type | |
| Protein binding | ARC1779 was shown to bind specifically to activated vWF. Activated vWF is scientifically recognized as the first stage of arterial thrombus formation and plays a significant role in the development of harmful blood clots. |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | September 19, 2023 at 7:00 am |
Uses
Platelet aggregation, thrombosis and acute coronary syndromes
How Egaptivon pegol works
ARC1779 can inhibit vWF activation and platelet function, which are both widely recognized as playing critical roles in clot formation which can critically impede blood flow to the heart.
Innovators Monograph
You find simplified version here Egaptivon pegol
